Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO

[1]  J. Semple,et al.  Recent advances in the mechanisms and treatment of immune thrombocytopenia , 2022, EBioMedicine.

[2]  P. Fenaux,et al.  Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia , 2021, Haematologica.

[3]  U. Platzbecker,et al.  Patient stratification in myelodysplastic syndromes: how a puzzle may become a map. , 2020, Hematology. American Society of Hematology. Education Program.

[4]  Lijuanli Li,et al.  Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis , 2020, Frontiers in Oncology.

[5]  Ivan Cancarevic,et al.  Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment , 2020, Cureus.

[6]  Xingmin Feng,et al.  Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome. , 2020, Haematologica.

[7]  M. Voso,et al.  Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial , 2019, Blood.

[8]  J. Bussel,et al.  Thrombopoietin receptor agonists: ten years later , 2019, Haematologica.

[9]  G. Garcia-Manero,et al.  Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. , 2019, Blood.

[10]  A. Verma,et al.  Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level , 2018, Nature Medicine.

[11]  W. Wiktor-Jedrzejczak,et al.  Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. , 2018, The Lancet. Haematology.

[12]  M. Mittelman.  Good news for patients with myelodysplastic syndromes and thrombocytopenia. , 2018, The Lancet. Haematology.

[13]  A. Giagounidis.  Current treatment algorithm for the management of lower-risk MDS. , 2017, Hematology. American Society of Hematology. Education Program.

[14]  J. Bussel,et al.  Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. , 2017, Blood.

[15]  R. Larson,et al.  Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy , 2017, British journal of haematology.

[16]  D. Kaplan,et al.  Revealing eltrombopag’s promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation , 2016, Haematologica.

[17]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[18]  P. Fenaux,et al.  Treatment of myelodysplastic syndrome with thrombomimetic drugs. , 2015, Seminars in hematology.

[19]  G. Mufti,et al.  Development and validation of a model to predict platelet response to romiplostim in patients with lower‐risk myelodysplastic syndromes , 2014, British journal of haematology.

[20]  G. Mufti,et al.  Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial , 2014, Leukemia.

[21]  W. Wiktor-Jedrzejczak,et al.  Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia , 2014, Cancer.

[22]  D. Cines,et al.  Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials , 2013, European journal of haematology.

[23]  M. Cazzola,et al.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.

[24]  D. Kuter.  The biology of thrombopoietin and thrombopoietin receptor agonists , 2013, International Journal of Hematology.

[25]  J. Bussel,et al.  Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy , 2013, British journal of haematology.

[26]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[27]  M. Ardanaz,et al.  Prognostic impact of severe thrombocytopenia in low‐risk myelodysplastic syndrome , 2011, Cancer.

[28]  M. Cazzola,et al.  Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) , 2011, Haematologica.

[29]  Luca Malcovati,et al.  Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome , 2011, Haematologica.

[30]  B. Chong,et al.  Romiplostim or standard of care in patients with immune thrombocytopenia. , 2010, The New England journal of medicine.

[31]  D. Kuter.  Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. , 2009, Annual review of medicine.

[32]  J. Luengo,et al.  Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist , 2009, Stem cells.

[33]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[35]  V. Broudy,et al.  AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. , 2004, Cytokine.

[36]  K. Kaushansky,et al.  The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production , 2002, Oncogene.

[37]  G. V. Kass.  An Exploratory Technique for Investigating Large Quantities of Categorical Data , 1980 .